Durham gene editing firm inks billion-dollar deal with Novartis


A gene editing firm in the Triangle has landed a deal worth up to $1.4 billion with the global pharmaceutical company.

Previous BEST IN FINANCE: Meet the 24 executives who serve as financial stewards of their organizations
Next First Bank extends growth streak with $181M deal in SC